Putting chirality to work: The strategy of chiral switches

被引：498

作者：

Agranat, I

Caner, H

Caldwell, A

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Biomed Sci, London SW7 2AZ, England

[2] Hebrew Univ Jerusalem, Dept Organ Chem, IL-91904 Jerusalem, Israel

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 10期

关键词：

D O I：

10.1038/nrd915

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Most of the new drugs reaching the market today are single enantiomers, rather than the racemic mixtures that dominated up to ten years ago. Many of the new single-enantiomer drugs were developed as such, but there are also important examples of new single-enantiomer drugs derived from 'chiral switches' of established racemates. Indeed, a well-timed chiral switch can offer enhanced therapy and further profitability as a 'line extension' of a major racemic drug with patents that are expiring.

引用

页码：753 / 768

页数：16

共 134 条

[41]

Eichelbaum M., 1996, ADV DRUG RES, V28, P1, DOI 10.1016/S0065-2490(96)80003-7

[42]

Eliel E.L., 1994, Stereochemistry of Organic Compounds

[43] STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE [J].